Risk of exacerbation of rheumatic disease after COVID-19 vaccination
International Journal of Rheumatic Diseases
; 26(Supplement 1):127.0, 2023.
Article
in English
| EMBASE | ID: covidwho-2228966
ABSTRACT
Objectives:
To investigate the risk of flare-ups after COVID-19 vaccination in patients with rheumatic disease. Method(s) A total of 1617 patients with rheumatic diseases were identified from three rheumatology clinics. Patients were interviewed for demographic data, disease activity, and vaccination status. Clinical disease flare up was determined independently by expert opinion by managing rheumatologists. Change of serum markers and medications were retrieved from medical records. The risk of exacerbation of rheumatic disease, change in serum markers, and escalation of rheumatic medications between vaccinated and non-vaccinated patients were determined using cox, linear and logistic regression models respectively. Possible confounding factors were also taken into consideration. Result(s) There were 562 (34.76%) patients received COVID-19 vaccine. After vaccination, rheumatic disease (HR = 2.10, P < 0.001), inflammatory arthritis (HR = 2.71, P < 0.001), rheumatoid arthritis (RA) (HR = 2.03, P = 0.002), spondyloarthritis (SpA) (HR = 4.78, P < 0.001), autoimmune disease (HR = 1.77, P = 0.01), and systemic lupus erythematosus (SLE) (HR = 1.99, P = 0.02) were associated with clinical flare up. Adult still's disease (B = 12.76, P = 0.03) was associated with an increase in CRP level. Escalation of rheumatic medications were not associated with COVID-19 vaccination in all diseases. Subgroup analyses showed only mRNA vaccine was associated with disease flare ups. Conclusion(s) COVID-19 vaccine was associated with minor disease flare up but not escalation of rheumatic medications. In the absence of absolute contraindications, full COVID-19 vaccination in patients with rheumatic disease should be encouraged by managing rheumatologists.
COVID-19 vaccine; DMARDs; flare up; medications; mRNA; rheumatic disease; rheumatoid arthritis; spondyloarthritis; systemic lupus erythematosus; adult; adult onset Still disease; adverse drug reaction; autoimmune disease; conference abstract; confounding variable; contraindication; controlled study; coronavirus disease 2019; demographics; disease exacerbation; drug therapy; female; human; human tissue; major clinical study; male; medical record; multicenter study; rheumatologist; rheumatology; side effect; spondylarthritis; vaccination; disease modifying antirheumatic drug; messenger RNA; RNA vaccine; SARS-CoV-2 vaccine
Full text:
Available
Collection:
Databases of international organizations
Database:
EMBASE
Type of study:
Prognostic study
Topics:
Vaccines
Language:
English
Journal:
International Journal of Rheumatic Diseases
Year:
2023
Document Type:
Article
Similar
MEDLINE
...
LILACS
LIS